Exelixis Inc

NASDAQ:EXELUnited States

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Contact Information

Headquarters

1851 Harbor Bay ParkwayALAMEDA, CA, United States 94502

Phone

650-837-7000

Fax

650-837-8300

Executives

Independent Chairman of the Board, Co-Founder

Stelios Papadopoulos

President, Chief Executive Officer, Director

Michael Morrissey

Chief Financial Officer, Executive Vice President

Christopher Senner

Executive Vice President - Discovery and Translational Research, Chief Scientific Officer

Dana Aftab

Executive Vice President, General Counsel, Secretary

Jeffrey Hessekiel